Thromboxane A3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Thromboxane A3
• 英文别名: (Z)-7-[(1S,3R,4S,5S)-3-[(1E,3S,5Z)-3-hydroxyocta-1,5-dienyl]-2,6-dioxabicyclo[3.1.1]heptan-4-yl]hept-5-enoic acid
• 化学式: C₂₀H₃₀O₅
• 分子量: 350.4
• InChiKey: NMZKLLJQNNTBRJ-OIXZZONUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  76
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
  申请人：Ghosal Shibnath

  公开号：US20050282781A1

  公开（公告）日：2005-12-22

  An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested/shown that C 20:5n-3 (and C 22:6 n-3 ) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.

  一项发明提供了有力证据，证明含氧二苯并-α-吡喃酮（DBPs及其共轭物）是希拉吉（阿育吠陀活力剂）的主要生物活性成分，其起源至少部分源自EPA和DHA。早期研究表明，在哺乳动物中，C-20多不饱和脂肪酸通过氧化酶和其他酶代谢，产生短寿命的前列腺素、白三烯和血栓素，这些物质结合特定的G蛋白偶联受体并传递细胞反应，如炎症、血管舒张、血压、疼痛等。但以前从未提出/展示过C20:5n-3（和C22:6 n-3）多不饱和脂肪酸，如EPA（和DHA），会转化为稳定的芳香代谢物DBPs，这些物质在生产者生物体中引发大量生物活性，并且还控制花生四烯酸衍生的前列腺素的合成和代谢。现在，归因于EPA和DHA的主要益处效应在很大程度上是由DBPs及其氨酰共轭物和二苯并-α-吡喃酮-色蛋白（DCPs）贡献的。由于EPA和DHA的高度不稳定性，当其被施用时，它们会代谢成大量无法控制的产物，其中一些在全身上是不可取的。相比之下，由于其稳定性，DBPs以有针对性和持续的方式执行生物反应调节剂（BRM）功能。本发明描述的DBPs的许多生物效应，以前被归因于EPA和DHA，即DBPs的前体。
• Prophylactic substance or composition
  申请人：SENTRACHEM LIMITED

  公开号：EP0106571A2

  公开（公告）日：1984-04-25

  The invention concerns a method of preventing the multiplication of viable cancer cells by the regular administration of a prophylactic amount of a precursor for the production, in vivo of one or more of the following eicosanoid mixtures and particularly GLA, AA and/or EPA.

  本发明涉及一种预防有活力癌细胞繁殖的方法，通过定期服用一定量的前体，在体内产生以下一种或多种二十碳烷混合物 特别是 GLA、AA 和/或 EPA。
• Eicosanoids for use in cancer therapy
  申请人：SENTRACHEM LIMITED

  公开号：EP0175468A2

  公开（公告）日：1986-03-26

  The invention comprises a method of normalising cellular eicosanoid balance by administering to a warm blooded animal an effective amount of a composition chosen from the group comprising eicosapentanoic acid (EPA), docosahexanoic acid (DHA) a mixture of EPA and DHA and a mixture of EPA, DHA and GLA. The invention also relates to compositions for normalising cellular eicosanoid balance for the preventing or treatment of cancer.

  本发明包括一种使细胞类二十碳烷平衡正常化的方法，其方法是向温血动物施用有效量的组合物，该组合物选自由二十碳五烷酸（EPA）、二十二碳六烷酸（DHA）、EPA 和 DHA 的混合物以及 EPA、DHA 和 GLA 的混合物组成的组。 本发明还涉及用于预防或治疗癌症的使细胞类二十碳烷平衡正常化的组合物。
• Medicament for curing arteriosclerosis, comprising pyrimido (2,1-b) benzothiazole derivative
  申请人：MECT CORPORATION

  公开号：EP0261439A2

  公开（公告）日：1988-03-30

  A medicament for curing arteriosclerosis which comprises pyrimido [2,1-b] benzothiazole derivative.

  一种治疗动脉硬化的药物，由嘧啶并[2,1-b]苯并噻唑衍生物组成。
• Pharmaceutical preparations containing polyunsaturated fatty acids, their esters or salts, together with antioxidant vitamins or provitamins
  申请人：PROSPA B.V.

  公开号：EP0699437A1

  公开（公告）日：1996-03-06

  Pharmaceutical preparations are described, useful in the prevention and/or treatment of atherosclerosis, of cardiovascular, nervous system, skin and malignant pathologies, containing 50 to 1000 mg of omega-3 fatty acids, their esters and their salts with inorganic and organic bases, as individual compounds or as a mixture, in combination with 10-40% by weight of antioxidant/reducing vitamins or provitamins.

  所述药物制剂可用于预防和/或治疗动脉粥样硬化、心血管、神经系统、皮肤和恶性病变，含有 50 至 1000 毫克欧米加-3 脂肪酸、其酯类和无机盐及有机碱盐，作为单独化合物或混合物，与 10-40% （按重量计）的抗氧化/还原维生素或维生素原结合使用。